Company Overview
Alpha Tau Medical Ltd. operates as a clinical-stage oncology therapeutics company dedicated to the research, development, and commercialization of diffusing alpha-emitters radiation therapy, commonly referred to as Alpha DaRT, specifically for the treatment of solid cancers. The enterprise functions within the healthcare sector and the biotechnology industry, positioning itself as a specialized entity focused on advanced therapeutic technologies rather than broad pharmaceutical distribution. The company's current market capitalization stands at $616.95M, while its annual revenue remains N/A, and it employs a workforce of 121 individuals to drive its clinical programs. These valuation figures indicate that the market values the company primarily on its potential future commercialization of Alpha DaRT technology rather than on current cash flows or established sales history typical of mature healthcare firms.
Financial Health
The company reports a net income of $-42,627,000 and an EBITDA of $-41,056,000, while its annual revenue is listed as N/A, revealing a significant gap between top-line activity and profitability that points to heavy investment in research and development costs. The reported free cash flow is $-19,703,876, which signifies that the company is currently burning cash to fund its clinical trials and operational expansion, thereby limiting its immediate financial flexibility for external investments or acquisitions. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability on a percentage basis due to its early-stage development status and lack of substantial sales volume. On the balance sheet, the company holds $73.13M in cash against $13.73M in debt, resulting in a debt-to-equity ratio of 17.80, which suggests a capital structure that relies heavily on equity financing rather than traditional leverage. The current ratio is 7.45, a figure that indicates strong short-term liquidity and an ample ability to cover current liabilities with available current assets despite the negative earnings. Return on Equity stands at -61.0% and Return on Assets is -27.6%, metrics that reveal management is currently generating negative returns on the capital deployed, a common characteristic for biotechnology firms in the clinical stage before product approval.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A because the company is not profitable, whereas the forward P/E is -16.46, a difference that implies the market is pricing in a trajectory where earnings are expected to turn positive in the future but are currently negative. The price-to-book ratio is 8.00, which indicates that the market is valuing the company's equity at a significant premium over its book value, reflecting high expectations for the potential success of its Alpha DaRT technology. The price-to-sales ratio is N/A and the EV/EBITDA is -13.58, suggesting that traditional valuation multiples are not applicable in the standard sense and that investors are relying on alternative metrics or intrinsic value assessments for this asset. The stock has traded between a 52-week low of $2.30 and a 52-week high of $8.60, meaning the current price sits within this historical range, fluctuating based on updates to clinical trial data and regulatory progress. The beta is 1.03, which explains that the stock's price volatility is slightly higher than the broader market, moving in tandem with general equity market trends but with added sensitivity specific to the biotechnology sector.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth rates against revenue growth, but the absence of historical growth data reflects the company's pre-revenue stage where financial expansion is driven by clinical milestones rather than sales volume. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings and capital back into its operations and research programs rather than distributing income to shareholders. This non-dividend profile is standard for clinical-stage biotechnology firms, where the primary strategy involves retaining capital to fund the expensive process of bringing new therapies to market. Consequently, the overall growth and income profile is characterized by a focus on capital appreciation potential through technological advancement rather than current income generation or dividend stability.